Positive Nipple Margins in Nipple-Sparing Mastectomy: Management of Nipples Containing Cancer or Atypia
Authors:
- 1 May 2024
- journal article
- research article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (8) , 5148-5156
Abstract
Nipple-sparing mastectomy (NSM) is an oncologically safe approach for breast cancer treatment and prevention; however, there are little long-term data to gKeywords
This publication has 40 references indexed in Scilit:
- The utility of intraoperative retroareolar margin frozen section assessment and the management of atypical epithelial proliferative lesions at the retroareolar margin in nipple-sparing mastectomiesAnnals of Diagnostic Pathology, 2021
- A novel nipple–areola complex involvement predictive index for indicating nipple-sparing mastectomy in breast cancer patientsBreast Cancer, 2019
- Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomyBreast Cancer Research and Treatment, 2018
- Preoperative MRI evaluation of lesion–nipple distance in breast cancer patients: thresholds for predicting occult nipple–areola complex involvementClinical Radiology, 2018
- Primary tumor location predicts the site of local relapse after nipple–areola complex (NAC) sparing mastectomyBreast Cancer Research and Treatment, 2017
- The diagnostic utility of preoperative breast magnetic resonance imaging (MRI) and/or intraoperative sub-nipple biopsy in nipple-sparing mastectomyEuropean Journal of Surgical Oncology, 2017
- Radiotherapy and nipple–areolar complex necrosis after nipple-sparing mastectomy: a systematic review and meta-analysisLa radiologia medica, 2016
- Nipple sparing mastectomy: Surgical and oncological outcomes from a national multicentric registry with 913 patients (1006 cases) over a six year periodThe Breast, 2016
- Therapeutic nipple-sparing mastectomy: trends based on a national cancer databaseThe American Journal of Surgery, 2014
- Nipple sparing mastectomy with nipple areola intraoperative radiotherapy: one thousand and one cases of a five years experience at the European institute of oncology of Milan (EIO)Breast Cancer Research and Treatment, 2009